LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get in on this burgeoning new trend. “These solutions are designed to reduce time and risk ...

“Since LabCorp acquired Covance, we have grown the CRO business to nearly $3 billion in annual revenue,” said John Ratliff, CEO of Covance. “We now join with Chiltern to create a market-leading CRO, ...

Digital clinical trials firm Medable is teaming up with Covance to allow the CRO to better navigate the COVID-19 disruption by using its virtual trial platform. Under the deal, financials of which ...

Laboratory Corporation of America Holdings or LabCorp LH recently announced that it has completed its much talked-about swap transaction with Envigo, a provider of nonclinical contract research ...

“We have an enormous database of patients, which includes their demographic information, their diagnosis information,” the WSJ reported LabCorp Chairman and Chief Executive Officer David King having ...

The yet-to-be-named new company will be publicly traded. Separating the laboratory testing work of LabCorp from the clinical trial services business, much of which came from acquisitions, will enable ...

Fortrea will make life-changing innovation possible by combining decades of experience with the nimbleness needed today to improve the drug development process. Fortrea intends to help customers drive ...

On July 28, 2022, Labcorp (NYSE: LH, $257.94; Market Capitalization: $23.3 billion), a leading global life sciences company, announced that its Board of Directors authorized a plan to spin-off ...

(RTTNews) - Life sciences company LabCorp (LH) announced Thursday that John Ratliff, currently CEO of Covance, will become CEO of LabCorp Diagnostics, and Dr. Paul Kirchgraber, currently senior vice ...